echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Mol Cancer (IF=41) The team of Zhou Yanbing from Qingdao University discovered the potential biomarkers of pancreatic cancer for the first time, which is expected to be used in clinical treatment

    Mol Cancer (IF=41) The team of Zhou Yanbing from Qingdao University discovered the potential biomarkers of pancreatic cancer for the first time, which is expected to be used in clinical treatment

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    iNature

    Pancreatic cancer (PC) is the deadliest solid tumor worldwide


    At present, surgical resection is still the main method for the treatment of pancreatic cancer, but nearly 70% to 80% of PC patients are diagnosed with advanced or locally advanced stage, and the possibility of radical tumor resection is only 8% to 12%


    On August 9, 2022, the team of Zhou Yanbing from Qingdao University published a research paper online entitled "TIPE3 is a candidate prognostic biomarker promoting tumor progression via elevating RAC1 in pancreatic cancer" in Molecular Cancer (IF=41) magazine.




    —END—The content is [iNature]
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.